Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | TRPC6 | Q9Y210 | 4/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 6/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23915569 | 0.80 | TRPA1 (0.41) | TRPA1TRPM8TRPV1CNR2HPGD | |
| SCHEMBL11565480 | 0.77 | HPGD (0.46) | TRPA1TRPM8TRPV1HPGDHTR2A | |
| SCHEMBL23909109 | 0.76 | TRPC6 (0.42) | TRPC6CNR2HTR2CCDK2DHFR | |
| SCHEMBL23909106 | 0.74 | XDH (0.46) | TRPC6XDH | |
| SCHEMBL21940549 | 0.73 | CNR2 (0.39) | TRPA1TRPM8TRPV1CNR2CDK2 | |
| SCHEMBL22023311 | 0.71 | XDH (0.44) | TRPC6CDK2XDH | |
| SCHEMBL29596850 | 0.71 | XDH (0.44) | TRPC6CDK2XDH | |
| SCHEMBL5565701 | 0.70 | ALDH1A1 (0.38) | TRPA1TRPM8TRPV1HPGDHTR2A | |
| SCHEMBL23966851 | 0.70 | TRPA1 (0.37) | TRPA1TRPM8TRPV1CNR2HPGD | |
| SCHEMBL1920066 | 0.69 | HPGD (0.47) | TRPA1TRPM8TRPV1HPGDHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | TRPA1 656/4885TRPM8 1596/4885TRPV1 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.